Cargando…
Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
The diuretic bumetanide failed to treat acute seizures due to hypoxic ischemic encephalopathy (HIE) in newborn babies and was associated with hearing loss (NEMO trial, Pressler et al., 2015). On the other hand, clinical and experimental observations suggest that the diuretic might provide novel ther...
Autores principales: | Ben-Ari, Yehezkel, Damier, Philippe, Lemonnier, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830840/ https://www.ncbi.nlm.nih.gov/pubmed/27147965 http://dx.doi.org/10.3389/fncel.2016.00090 |
Ejemplares similares
-
Bumetanide for autism: more eye contact, less amygdala activation
por: Hadjikhani, Nouchine, et al.
Publicado: (2018) -
A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders
por: Delpire, Eric, et al.
Publicado: (2022) -
The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis
por: Ben-Ari, Yehezkel, et al.
Publicado: (2022) -
A randomised controlled trial of bumetanide in the treatment of autism in children
por: Lemonnier, E, et al.
Publicado: (2012) -
Comparison of Brain Maturation among Species: An Example in Translational Research Suggesting the Possible Use of Bumetanide in Newborn
por: Pressler, Ronit, et al.
Publicado: (2013)